BACKGROUND/AIM: Interferons (IFN) are currently being used to treat melanoma, including some patients with uveal melanoma. IFN is thought to inhibit tumour growth through downregulation of the c-myc oncogene; the overexpression of which has been shown to be associated with resistance in cell lines. The aim of this study was to investigate the relation between c-myc gene expression and IFN sensitivity in a series of uveal melanomas in a short term chemosensitivity assay. METHODS: Tumours from 45 patients with uveal melanoma who had undergone enucleation were studied. The ATP chemosensitivity assay was used to study sensitivity to IFN-alpha-2b in freshly isolated cells from each tumour. Flow cytometry was used to assess c-myc expression in formalin fixed material from the primary specimens. RESULTS: There was a wide range of IFN sensitivity between the specimens whereas c-myc expression was universal and present in 80% of the tumour cells in 80% of the specimens. Higher c-myc expression was associated with IFN-alpha resistance as measured by the maximum percentage of inhibition (p = 0.05) and there was a trend with the IFN sensitivity index (p = 0.07). CONCLUSIONS: These results demonstrate that tumours with high c-myc expression are also associated with IFN resistance. Future research is required to explore the potential of c-myc gene manipulation combined with IFN therapy.
BACKGROUND/AIM: Interferons (IFN) are currently being used to treat melanoma, including some patients with uveal melanoma. IFN is thought to inhibit tumour growth through downregulation of the c-myc oncogene; the overexpression of which has been shown to be associated with resistance in cell lines. The aim of this study was to investigate the relation between c-myc gene expression and IFN sensitivity in a series of uveal melanomas in a short term chemosensitivity assay. METHODS:Tumours from 45 patients with uveal melanoma who had undergone enucleation were studied. The ATP chemosensitivity assay was used to study sensitivity to IFN-alpha-2b in freshly isolated cells from each tumour. Flow cytometry was used to assess c-myc expression in formalin fixed material from the primary specimens. RESULTS: There was a wide range of IFN sensitivity between the specimens whereas c-myc expression was universal and present in 80% of the tumour cells in 80% of the specimens. Higher c-myc expression was associated with IFN-alpha resistance as measured by the maximum percentage of inhibition (p = 0.05) and there was a trend with the IFN sensitivity index (p = 0.07). CONCLUSIONS: These results demonstrate that tumours with high c-myc expression are also associated with IFN resistance. Future research is required to explore the potential of c-myc gene manipulation combined with IFN therapy.
Authors: C Ericsson; S Seregard; A Bartolazzi; E Levitskaya; S Ferrone; R Kiessling; O Larsson Journal: Invest Ophthalmol Vis Sci Date: 2001-09 Impact factor: 4.799
Authors: S Ozawa; H Shinohara; H O Kanayama ; C J Bruns; C D Bucana; L M Ellis; D W Davis; I J Fidler Journal: Neoplasia Date: 2001 Mar-Apr Impact factor: 5.715
Authors: J C Becker; P Terheyden; E Kämpgen; S Wagner; C Neumann; D Schadendorf; A Steinmann; G Wittenberg; W Lieb; E-B Bröcker Journal: Br J Cancer Date: 2002-10-07 Impact factor: 7.640
Authors: Aaron Farnsworth; Anathea S Flaman; Shiv S Prasad; Caroline Gravel; Andrew Williams; Carole L Yauk; Xuguang Li Journal: PLoS One Date: 2010-06-09 Impact factor: 3.240
Authors: Véronique Mathieu; Christine Pirker; Elisabeth Martin de Lassalle; Mathieu Vernier; Tatjana Mijatovic; Nancy DeNeve; Jean-François Gaussin; Mischael Dehoux; Florence Lefranc; Walter Berger; Robert Kiss Journal: J Cell Mol Med Date: 2009-02-20 Impact factor: 5.310
Authors: Juan C Corredor; Nicole Redding; Karen Bloté; Stephen M Robbins; Donna L Senger; John C Bell; Paul Beaudry Journal: Mol Ther Oncolytics Date: 2016-03-16 Impact factor: 7.200